> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Approves Kynmobi for Parkinson’s ‘Off’ Time
- URL: https://www.fdaweb.com/fda-approves-kynmobi-for-parkinsons-off-time/
- Published: 2020-05-22T12:00:00.000Z
- Updated: 2026-09-14T16:15:46.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5146850

FDA has approved Sunovion’s Kynmobi (apomorphine hydrochloride) to treat the so-called “off-time” when Parkinson’s disease symptoms are not well controlled with oral medication. The Michael J. Fox Foundation for Parkinson’s Research [says](https://www.marketwatch.com/press-release/second-parkinsons-therapy-funded-by-the-michael-j-fox-foundation-receives-fda-approval-and-advances-to-market-2020-05-22?tesla=y&ref=fdaweb.com) this is the second agency approval of a drug the foundation helped to fund.

The foundation helped provide more than $1.4 million to fund Kynmobi Phase 1 trials by Cynapsus Therapeutics in 2012 and 2014\. Kynmobi is described as a thin-film formulation of apomorphine placed under the tongue.

Previously the foundation supported the early development of Acorda’s Inbrija (levodopa inhalation powder), also indicated for “off-time” use.